Psychedelic substances, such as LSD and psilocybin, are known for their effects on the brain that can produce profound changes in perception, mood and consciousness.
Small Pharma has announced results from its Phase 2a trial of its intravenous formulation of DMT – SPL026 – demonstrating improvement in depression and anxiety.
Using machine learning analysis, researchers have determined that a mystical and insightful psychedelic drug experience may be linked to long-term reductions in anxiety and depression symptoms.
As psychedelic research increases, and a number of policy developments across the likes of the US, Canada and Australia are now enabling the delivery of psychedelic...
University of Cincinnati researchers have examined post-treatment journals kept by participants in a smoking cessation study that found psychedelics were effective in helping some people quit...
PharmaDrug Inc.
The US Food and Drug Administration (FDA) has given IND approval for a Phase 2b study of a synthetic formulation of 5-MeO-DMT – BPL-003.
Doug Drysdale, CEO of Cybin Inc.,
In what marks a significant finding in the advancement of psychedelic research, a new study has demonstrated that the location of serotonin 2A receptors (5-HT2A) is...
Reset Mind Sciences, a wholly-owned subsidiary of Little Green Pharma, has received Human Research Ethics Committee (HREC) approval for a trial investigating psilocybin-assisted psychotherapy for the...